I am downgrading Equifax stock to a hold rating due to weak FY25 guidance, soft mortgage inquiry outlook, and hiring market pressures. Despite solid 4Q24 results and medium-term growth potential, the near-term earnings outlook is poor with decelerating revenue and EPS growth. Elevated mortgage rates and declining hiring volumes are significant headwinds, limiting EFX's ability to sustain recent growth rates.
Equifax Inc. (NYSE:EFX ) Q4 2024 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Trevor Burns - Senior Vice President, Head of Corporate Investor Relations Mark Begor - Chief Executive Officer John Gamble - Chief Financial Officer Conference Call Participants Jeff Muller - Baird Manav Patnaik - Barclays Andrew Steinerman - JPMorgan Toni Kaplan - Morgan Stanley Faiza Alwy - Deutsche Bank Kyle Peterson - Needham Craig Huber - Huber Research Partners Jason Haas - Wells Fargo Owen Lau - Oppenheimer Andrew Nicholas - William Blair Kelsey Zhu - Autonomous Research Scott Wurtzel - Wolfe Research Matt O'Neill - FT Partners Simon Clinch - Redburn Atlantic Arthur Truslove - Citi George Tong - Goldman Sachs Operator Greetings and welcome to the Equifax Corporate's Fourth Quarter 2024 Earning Conference Call. This time, all participants are in a listen-only mode.
Robust growth across segments drives EFX's top line in the fourth quarter of 2024.
For Equifax, macro headwinds from a job market slowdown and the volatile mortgage market — where uneven loan demand has been a hallmark amid relatively high interest rates — have impacted top-line momentum and forward-looking guidance. As discussed during an earnings call with analysts Thursday (Feb.
The headline numbers for Equifax (EFX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Equifax (EFX) came out with quarterly earnings of $2.12 per share, beating the Zacks Consensus Estimate of $2.10 per share. This compares to earnings of $1.81 per share a year ago.
EFX's fourth-quarter 2024 revenues are expected to have increased due to healthy mortgage activities.
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Equifax (EFX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Equifax (EFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company's stock surged over 100% after positive 96-week results from its phase 2b SYMMETRY study using EFX to treat F4 compensated cirrhosis due to MASH patients. The company achieved a significant reversal of cirrhosis, with 39% of patients showing improvement compared to 15% on placebo, highlighting EFX's efficacy. Upcoming catalysts include phase 3 SYNCHRONY studies targeting F1-F3 and F2-F3 MASH patients, with data expected in the first half of 2026 and 2027, respectively.
Equifax has agreed to a settlement and consent order that will resolve Consumer Financial Protection Bureau (CFPB) allegations that the consumer reporting agency failed to take steps to ensure the accuracy of its credit reports.
The U.S. Consumer Financial Protection Bureau announced on Friday it had fined credit reporting bureau Equifax $15 million for failing to sufficiently investigate consumer disputes of its credit reports.